TARS News and Press, Tarsus Pharmaceuticals Inc. From 08/11/23

2023-08-11 11:19:08 ET Tarsus Pharmaceuticals press release ( NASDAQ: TARS ): Q2 GAAP EPS of -$1.17. For further details see: Tarsus Pharmaceuticals GAAP EPS of -$1.17

XDEMVY™ (lotilaner ophthalmic solution) 0.25% received FDA approval for the treatment for Demodex blepharitis On track to have XDEMVY and sales force in market by the end of August 2023 Completed enrollment of Galatea, a Phase 2a trial evaluating TP-04 for Rosacea, with t...

2023-08-02 05:50:42 ET Tarsus Pharmaceuticals ( NASDAQ: TARS ) prices underwritten offering of 5,714,285 shares at a public offering price of $17.50 per share. Underwriters have a 30-day option to purchase up to an additional 857,142 shares. Gross proceeds are expected...

IRVINE, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye ca...

2023-07-31 17:11:02 ET Tarsus Pharmaceuticals ( NASDAQ: TARS ) has proposed to raise $100 million through an underwritten public offering of shares of its common stock, the company said Monday. The underwriters of the proposed offering have a 30-day option to purchase up...

IRVINE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye ca...

2023-07-25 17:56:43 ET Summary Tarsus Pharmaceuticals, Inc. achieved FDA approval of XDEMVY for the treatment of patients with Demodex blepharitis; XDEMVY for this indication could offer $1 billion + peak net sales potential. Results from the phase 2 study using XDEMVY [TP-03] for...

2023-07-25 12:09:08 ET Gainers: Electra Battery Materials ( ELBM ) +72% . Bullfrog AI Holdings ( BFRG ) +38% . Kiniksa Pharmaceuticals ( KNSA ) +30% . Steakholder Foods ( STKH ) +25% . Galecto ( GLTO ) +23% . Rigetti Computin...

2023-07-25 11:17:07 ET Tarsus Pharmaceuticals ( NASDAQ: TARS ) announced Tuesday that the FDA greenlighted its lead asset TP-03 as a treatment for the eyelid disorder Demodex blepharitis. Demodex blepharitis affects approximately 25M eyecare patients in the U.S., with a prevalen...

2023-07-25 10:18:59 ET Gainers: Bullfrog AI ( BFRG ) +35% . Carmell Therapeutics ( CTCX ) +32% . Kiniksa Pharmaceuticals ( KNSA ) +21% . Galecto ( GLTO ) +18% . Akebia Therapeutics ( AKBA ) +16% . Losers: NeuroOne Med...